Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of ...

Black race, regardless of cytogenetics, was found to be associated with poorer survival in a 30-year retrospective analysis of clinical trials involving patients with acute myeloid leukemia (AML) ...

Apple recently issued a fresh privacy-focused warning to iPhone users: avoid using Google Chrome (and certain Google apps).

A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...

Trump’s new National Security Strategy places the main geopolitical focus on the Americas and calls on the region to help ...

Bristol Myers Squibb (NYSE: BMY) reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual ...

Mercedes has revealed its second-generation GLB in full, offering seven-seat versatility and almost 400 miles of range. On ...

Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx1This Columvi combination is available off-the-shelf and could offer a ...

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

President Donald Trump hosted the first Kennedy Center Honors ceremony of his second term last weekend, and one reporter in ...

The triplet regimen of azacitidine, venetoclax, and tagraxofusp showed high complete response rates in both untreated and relapsed/refractory BPDCN patients. Safety profile of the triplet was ...